RMi Pre-opening: Waiting to be judged

January 6, 2026 8:18am

Most sector companies are preparing their presentations foe the JP Morgan Healthcare Conference

News: Arrowhead Pharmaceuticals (ARWR +$9.13 or 14.29% pre-open) its gene-silencing approach delivered almost double the amount of weight loss over 4 months as Eli Lilly's (LLY) Zepbound. ARWRs drug, ARO-INHBE, works by silencing the gene that produces activin E. Activin E plays a role in fat utilization and energy balance.

Pre-open Signals: 3 Positive and 1 Negative; If you understand probabilities, the inevitable is easier to maneuver

Never leave retail investor uninformed … I say what others won’t, so you can do what others can’t! 

No Don Quixote as I continually ask, what do all these stock sources, I-Banks and brokers do for you in providing daily information? Availability of data have made intel both complex; I see myself as a collector and my responsibility is to further identify and interpret data to bridge some gaps in an investment decision.

Monday’s RMi Closing Bell: The risk of expectation includes mitigation … https://www.regmedinvestors.com/articles/14254

RMi Research Note: Capricor Therapeutics (CAPR) DUMP before the next big SLUMP! … https://www.regmedinvestors.com/articles/14249

RMi Research Note: Harvard Apparatus GT (OTCQB: HRGN): I reiterate WHO is pumping the volume and share pricing? … https://www.regmedinvestors.com/articles/13812   

Tuesday: The pre-open Dow futures are DOWN -0.04% or ( -19 points), the S&P futures are UP +0.08% or (+5 points) and the Nasdaq futures are UP +0.27% or (+68 points)

• U.S. stock futures are mixed on Tuesday, 1/6/26
• European markets are up and remain positive,
• Asia Pacific markets were mixed.

Economic Data:  S&P PMIs

• On Friday, the December jobs report is expected to show a slowdown in hiring in the final month of 2025, with economists expecting nonfarm payrolls to grow by 55,000, down from November's job gains of 64,000. The unemployment rate, which hit a four-year high of 4.6% in November, is expected to fall by 0.1%.

Henry’omics: We need to more than consider the market’s setting to grasp the micro re “our” universe of cell and gene therapy companies

• Monday: The Dow closed UP +594.79 points or +1.23%, the S&P closed UP +43.58 points or +0.64% while the Nasdaq closed UP +160.193 points or +0.69%
• Friday: The Dow closed UP +319.10 points or +0.66%, the S&P closed UP +12.97 points or +0.19% while the Nasdaq closed DOWN -6.362 points or -0.03%
• Thursday was New Year’s holiday
• Last Wednesday: The Dow closed DOWN -303.77 points or -0.63%, the S&P closed DOWN -50.74 points or -0.74% while the Nasdaq closed DOWN -177.089 points or -0.76%
• The previous Tuesday: The Dow closed DOWN -94.87 points or -0.20%, the S&P closed DOWN -9.50 points or -0.14% while the Nasdaq closed DOWN -55.27 points or -0.24%

• Last week: The S&P 500 was down -1.2%, the Dow was down -1.3% and the Nasdaq was down -1.5%.
• The previous week: The S&P 500 was up +1.4%, the Dow +1% and the Nasdaq was also up +0.1%
• December ended with the S&P 500 up +16.4%, the Dow +13% and the Nasdaq +20.4%

Q1/26 – Q1 – 1 holiday, 1 negative and 1 positive close  

Q4 – December,

• 1 holiday, 8 positive and 12 negative closes
• November, 1 holiday, 8 positive and 11 negative sessions
• October, 1 neutral, 10 positive and 12 negative closes

Companies in my headlights – It’s your decision; I provide ideas and context

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.  A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

Arrowhead Pharmaceuticals (ARWR) closed down -$3.91 with a positive +$9.13 or +14.29% pre-open

Capricor Therapeutics (CAPR) closed down -$3.50 after Friday’s -$0.55 (-1.91% to $28.31), Wednesday’s -$1.03 and last Tuesday’s -$0.15, with a positive +$0.19 or +0.77% pre-open – SELL

• As CAPR’s investment bank jumps into protecting its offering pricing – Don’t be SWAYED by their BUYING!!
• I am STICKING to my CONVICTION that CAPR is overbought and whose valuation is disconnected from fundamentals.
• Doubts still abound re: regulatory fragility and marginal HOPE-3 results and valuation concerns remain a key hang-up!
• CAPR remains a structurally challenged, chronically unprofitable company whose valuation is disconnected from fundamentals.
• It has begun; timing will be everything!
• The higher CAPR rises, the steeper the fall!

Vertex (VRTX) closed down -$3,33 after Friday’s -$1.23 with a positive +$3.43or +0.76% pre-open

Wave Life Sciences (WVE) closed down -$0.95 after Friday’s -$1.05 with a positive +3.09 or +20.59% pre-open

The BOTTOM LINE: Welcome to my world of defining the “grey’ in our universe!

The Santa Claus rally" — during the last 5 trading days of December and first 2 of January — has sputtered.

Welcome to my world of defining the “grey’ in our universe!

• I hate to be so negative or contrarian but, this is a NO spin zone and facts and truth are its products; I can always be WRONG but, I am mostly EARLY!
• if I wanted to be liked, I wouldn’t have been an analyst/journalist.

Investors are hoping for continued momentum, as they gauge the prospects for a Santa Claus rally.

• After a surprise drop in inflation and lukewarm labor market data left betting on possible 2026 interest-rate cuts

• In the week ahead, those investors still around after the New year will forget the “Santa Claus rally

January – 2nd week’s session

• 1 /3 - Monday closed negative with 18 incliners, 21 decliners and 1 flat

First week, January:

• 1 /2 - Friday closed positive with 18 incliners, 17 decliners and 5 flats
• 1/1 -Thursday was a holiday, New Years Day

Last week of December, Q4 and FY25

• Wednesday closed negative with 18 positive, 22 negative and 5 flats
• Tuesday closed negative with 7 positive, 31 negative and 2 flats
• Monday closed negative with 12 positive, 24 negative and 4 flats

As the leading voice of cell and gene therapy investors; I am NOT always a doom and gloom analyst/journalist but a man who has been “there” (BUY, SELL, VC and multiple operating roles) with the gray hair and a readership following with real numbers to prove it!

• I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed.